Healthcare / Medical DistributionNasdaqCM
$0.55
+0.02 (+4.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $414226.00 · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
6.0x
↓ROE
-0.5%
↓Gross Margin
11.9%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+27.2%
FCF CAGR
-49.3%
FCF margin
2.0%
FCF / Net income
-15.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.3M · net income $-27056.0 · FCF $414226.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $20.3M | $20.3M | $16.7M | $12.6M |
| Net Income | $-27056.00 | $-27056.00 | $1.3M | $998196.00 |
| EBITDA | $1.2M | $1.2M | $2.5M | $1.8M |
| EPS | -0.00 | -0.00 | 0.12 | 0.09 |
| Gross Margin | 11.9% | 11.9% | 21.3% | 21.8% |
| Operating Margin | 1.0% | 1.0% | 10.0% | 8.6% |
| Net Margin | -0.1% | -0.1% | 8.0% | 7.9% |
| Balance Sheet | ||||
| Debt/Equity | 0.48 | 0.48 | 0.49 | 1.18 |
| Current Ratio | 2.93 | 2.93 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $414226.00 | $414226.00 | $-482348.00 | $1.6M |
| Returns | ||||
| ROE | -0.5% | -0.5% | 31.3% | 170.6% |
| Valuation | ||||
| EV/EBITDA | 6.00 | 6.00 | — | — |
| P/B | 1.12 | 1.12 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 21.7% | 21.7% | 32.9% | — |
| EPS Growth | -102.5% | -102.5% | 33.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.12 → -0.00
Residual
-53.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.